eMed Chief Wellness Officer Tom Brady and eMed CEO Linda Yaccarino discuss GLP-1 market growth and the company’s latest funding round on ‘Mornings with Maria’.
Such as the market for GLP-1 weight loss medications is exploding towards a projected $150 billion, NFL legend Tom Brady is entering the arena – not to promote a magic pill, but to infuse the clinical wave with his signature ‘TB12’ discipline.
“Making a difference in other people’s lives, trying to share some of the things that have been on my mind and that I’ve learned from incredible mentors, understanding and trying to inspire the different people that have come into my life to deliver the messages that I’ve been able to get, that have helped me kind of make my dream come true, and I want to do that for others,” Brady said in an exclusive “Mornings with Maria” interview that aired Thursday.
Seven-time Super Bowl champion and eMed CEO Linda Yaccarino joined forces to announce a massive $200 million funding round, valuing the digital healthcare company at more than $2 billion. The duo aims to revolutionize “population health” by using AI and clinical surveillance to provide employers with a sustainable way to offer GLP-1 weight loss medications such as Ozempic and Mounjaro, while reducing corporate insurance claims.
“The increase confirms tremendous momentum and establishes us as the definitive public health company, helping employers break runaway health care costs and break their cost curve,” Yaccarino told Bartiromo.
TOM BRADY SAYS POST-NFL LIFE IS ABOUT ‘BUILDING TRUST’ WHEN HE PLAYS BUSINESS WITH HERTZ
“When you have people who are overweight or obese, their health care costs are twice as high as the average worker who is not obese,” she continued. “So that’s the question that hasn’t been answered yet: that eMed can finally step in and deliver these solutions to employers across the country.”
Tom Brady at the Fanatics Flag Football Classic Press Conference & Practice held at BMO Stadium on March 20, 2026 in Los Angeles, California. (Getty Images)
While many Americans use GLP-1s As an easy solution to weight loss, Brady sees the eMed platform as a kickstart for those who lack the biological benefit of naturally high willpower. He emphasizes that medication should be based on a foundation of clinical support and personal responsibility.
“This isn’t about shortcuts for anyone. This is about a well-executed program that allows people to jumpstart their health journey in some way,” Brady clarified. “I was fortunate to be surrounded by the best professionals, the best doctors, the best trainers, the best nutritionists. And I realized how lucky I was to have that guidance.”
“I really want to break the stigma around the fact that, you know, discipline, hard work and willpower are something that we’re born with. I was born with that and I have the ability to do that. I think there’s a lot of other people who feel like that’s something that’s more of a struggle,” he added. “But we also have to be able to support those people.”
Seven-time Super Bowl Champion Tom Brady and Aescape CEO Eric Litman discuss the NFL star’s partnership with next-generation AI massage technology in “The Claman Countdown.”
Brady went on to explain how his most valuable asset required a level of maintenance that is only now becoming mainstream.
“I realized that because I was an athlete, my body was my property,” the former quarterback said. “If I loved playing football and being on the field, I like to give my best. I had to treat my body in a very specific way. I tried to do a lot of muscle work to repair injured tissue. I hydrated all the time. I tried to eat a low-inflammatory diet. I tried to get enough rest.”
“How can I ever stop? This is my life, I tell you, I’m so obsessed with working out. I would feel terrible and worse if I didn’t exercise all the time. I feel like I have a lot of energy…I want to stay active. I have three kids. I want to go outside and play basketball and swim and hit the golf ball and play volleyball with my daughter in the backyard,” Brady said.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Novo Nordisk President and CEO Mike Doustdar joins ‘Mornings with Maria’ to discuss the launch of the first GLP-1 weight loss pill in the US, the lawsuit against Hims & Hers and discussions with the Trump administration over drug pricing.
Yaccarino — the former CEO of
“Ninety percent of people stay on our program. They do two things: First, and most importantly, as Tom was referring to, they get healthier,” she said. “And when you get people on the show, when you deliver those health outcomes, that’s the secret sauce for employers, for CEOs and CFOs – who you have on your show all the time – because they get their return on their investment.”
